CNTX Insider Trading
Insider Ownership Percentage: 3.04%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Context Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Context Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Context Therapeutics Share Price & Price History
Current Price: $0.55
Price Change: ▼ Price Decrease of -0.0609 (-9.95%)
As of 04/1/2025 05:00 PM ET
Context Therapeutics Insider Trading History
Context Therapeutics Institutional Trading History
Data available starting January 2016
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More on Context Therapeutics
Volume
209,250 shs
Average Volume
391,419 shs
Market Capitalization
$49.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06